EA201891439A1 - Трициклические соединения и их композиции в качестве ингибиторов киназ - Google Patents

Трициклические соединения и их композиции в качестве ингибиторов киназ

Info

Publication number
EA201891439A1
EA201891439A1 EA201891439A EA201891439A EA201891439A1 EA 201891439 A1 EA201891439 A1 EA 201891439A1 EA 201891439 A EA201891439 A EA 201891439A EA 201891439 A EA201891439 A EA 201891439A EA 201891439 A1 EA201891439 A1 EA 201891439A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
compounds
kinaz
inhibitor
tricyclic compounds
Prior art date
Application number
EA201891439A
Other languages
English (en)
Inventor
Роберт Джон Аверса
Мэттью Т. Бургер
Майкл Патрик Диллон
мл. Томас А. Динин
Раджеш Карки
Савитхри Рамуртхи
Вивек Раунияр
Ричард РОБИНСОН
Патрик Джеймс Сарвер
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201891439A1 publication Critical patent/EA201891439A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

В настоящем изобретении предлагаются описанные в изобретении соединения формулы (A)и их соли, и терапевтическое применение этих соединений для лечения нарушений, связанных с активностью Raf-киназы. Кроме того, в изобретении предлагаются фармацевтические композиции, включающие эти соединения, и композиции, включающие эти соединения и котерапевтическое средство, и способы применения композиций и комбинаций для лечения состояний, в том числе раковых заболеваний.
EA201891439A 2015-12-18 2016-12-15 Трициклические соединения и их композиции в качестве ингибиторов киназ EA201891439A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562269252P 2015-12-18 2015-12-18
PCT/IB2016/057633 WO2017103824A1 (en) 2015-12-18 2016-12-15 Tricyclic compounds and compositions as kinase inhibitors

Publications (1)

Publication Number Publication Date
EA201891439A1 true EA201891439A1 (ru) 2018-12-28

Family

ID=57570893

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891439A EA201891439A1 (ru) 2015-12-18 2016-12-15 Трициклические соединения и их композиции в качестве ингибиторов киназ

Country Status (12)

Country Link
US (1) US10377770B2 (ru)
EP (1) EP3390404B1 (ru)
JP (1) JP6847954B2 (ru)
KR (1) KR20180095595A (ru)
CN (1) CN108699065B (ru)
AU (1) AU2016371387B2 (ru)
BR (1) BR112018012292A2 (ru)
CA (1) CA3008098A1 (ru)
EA (1) EA201891439A1 (ru)
ES (1) ES2892624T3 (ru)
MX (1) MX2018007517A (ru)
WO (1) WO2017103824A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107698586B (zh) * 2017-09-19 2020-02-07 广州大学 一种由铜化合物催化制备吡啶并喹唑啉酮类化合物的方法
CN113264945B (zh) * 2020-02-17 2022-11-22 江苏恒瑞医药股份有限公司 一种螺环衍生物、其制备方法及其在医药上的应用
CN113429440B (zh) * 2020-03-23 2023-05-12 江苏恒瑞医药股份有限公司 一种螺环化合物的前药、其制备方法及其在医药上的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
BRPI0512075A (pt) 2004-06-15 2008-02-06 Astrazeneca Ab composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença
EP1871773A1 (en) * 2005-03-17 2008-01-02 Novartis AG N-[3-(1-amino-5,6,7,8-tetrahydro-2,4,4b-triazafluoren-9-yl)-phenyl]benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
US7846923B2 (en) 2006-05-11 2010-12-07 Irm Llc Compounds and compositions as protein kinase inhbitors
CA2784807C (en) * 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
KR20130087020A (ko) * 2010-09-16 2013-08-05 허치슨 메디파르마 리미티드 축합 헤테로아릴 및 그 용도

Also Published As

Publication number Publication date
EP3390404B1 (en) 2021-07-21
ES2892624T3 (es) 2022-02-04
EP3390404A1 (en) 2018-10-24
US10377770B2 (en) 2019-08-13
JP6847954B2 (ja) 2021-03-24
KR20180095595A (ko) 2018-08-27
CA3008098A1 (en) 2017-06-22
BR112018012292A2 (pt) 2018-11-27
US20180362542A1 (en) 2018-12-20
AU2016371387A1 (en) 2018-07-05
AU2016371387B2 (en) 2019-11-14
JP2018537508A (ja) 2018-12-20
WO2017103824A1 (en) 2017-06-22
MX2018007517A (es) 2018-08-01
CN108699065B (zh) 2021-08-31
CN108699065A (zh) 2018-10-23

Similar Documents

Publication Publication Date Title
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
CR20180374A (es) Compuestos heterocíclicos como inmunomoduladores
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
MD20170016A2 (ru) Аминопиримидиновые соединения в качестве ингибиторов JAK
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA202090291A3 (ru) Производные бипиразола в качестве ингибиторов jak
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
CL2017000290A1 (es) Inhibidores de la proteína kinasa c y métodos de su uso.
EA201692487A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
PH12016502353A1 (en) Pharmaceutical composition
EA201790745A1 (ru) Трициклические соединения
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
EA201792057A1 (ru) Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы
EA201791933A1 (ru) Ингибирование активности olig2